Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Industry, Sector and Symbol
Industry Technical & System Software
Sub-IndustryN/A
SectorComputer and Technology
Phone+1-250-7084272
Debt
Current Ratio20.93
Quick Ratio20.29
Price-To-Earnings
Sales & Book Value
Annual SalesC$466,000.00
Price / Sales1,774.62
Price / Cash Flow6.05
Price / Book6.60
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees33
OptionableNot Optionable
Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."
How were Aurinia Pharmaceuticals' earnings last quarter?
Aurinia Pharmaceuticals Inc (TSE:AUP) posted its earnings results on Thursday, November, 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.05. The firm had revenue of $0.49 million for the quarter, compared to analysts' expectations of $0.09 million. View Aurinia Pharmaceuticals' Earnings History.
When is Aurinia Pharmaceuticals' next earnings date?
Has Aurinia Pharmaceuticals been receiving favorable news coverage?
Media coverage about AUP stock has trended positive on Thursday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include 99 Wuxian (NNW), Absolute Software (ABT), Artilium (ARTA), Computer Modelling Group (CMG), Covata (CVT), Dotdigital Group (DOTD), Eckoh (ECK), Electronic Data Processing (EDP), Emis Group (EMIS), Escher Group (ESCH), EU supply (EUSP), GB Group (GBG), Gresham Technologies (GHT), Ideagen (IDEA) and IDOX (IDOX).
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 60)
- Mr. Michael R. Martin, Co-Founder & COO
- Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
- Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
- Dr. Neil Solomons M.D., Chief Medical Officer
How do I buy shares of Aurinia Pharmaceuticals?
Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of AUP stock can currently be purchased for approximately C$9.69.
What is Aurinia Pharmaceuticals' official website?
How can I contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.
MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days.
